MX2022011964A - Moduladores de mtorc1 y usos de los mismos. - Google Patents
Moduladores de mtorc1 y usos de los mismos.Info
- Publication number
- MX2022011964A MX2022011964A MX2022011964A MX2022011964A MX2022011964A MX 2022011964 A MX2022011964 A MX 2022011964A MX 2022011964 A MX2022011964 A MX 2022011964A MX 2022011964 A MX2022011964 A MX 2022011964A MX 2022011964 A MX2022011964 A MX 2022011964A
- Authority
- MX
- Mexico
- Prior art keywords
- mtorc1
- modulators
- diseases
- salts
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Burglar Alarm Systems (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063001144P | 2020-03-27 | 2020-03-27 | |
| US202063001177P | 2020-03-27 | 2020-03-27 | |
| US202063001187P | 2020-03-27 | 2020-03-27 | |
| US202063019176P | 2020-05-01 | 2020-05-01 | |
| US202063054763P | 2020-07-21 | 2020-07-21 | |
| US202063054762P | 2020-07-21 | 2020-07-21 | |
| US202063054768P | 2020-07-21 | 2020-07-21 | |
| PCT/US2021/024536 WO2021195599A1 (en) | 2020-03-27 | 2021-03-26 | Mtorc1 modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011964A true MX2022011964A (es) | 2022-12-02 |
Family
ID=77892684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011964A MX2022011964A (es) | 2020-03-27 | 2021-03-26 | Moduladores de mtorc1 y usos de los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11634432B2 (enExample) |
| EP (1) | EP4126229A4 (enExample) |
| JP (2) | JP7606591B2 (enExample) |
| KR (2) | KR102805250B1 (enExample) |
| CN (2) | CN115776907B (enExample) |
| AU (2) | AU2021241718B2 (enExample) |
| CA (1) | CA3173722A1 (enExample) |
| IL (1) | IL296828A (enExample) |
| MX (1) | MX2022011964A (enExample) |
| WO (1) | WO2021195599A1 (enExample) |
| ZA (1) | ZA202210888B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10980784B2 (en) | 2018-06-15 | 2021-04-20 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| CA3127448C (en) | 2019-01-22 | 2024-06-04 | Aeovian Pharmaceuticals, Inc. | Mtorc modulators and uses thereof |
| EP4069223A4 (en) | 2019-12-05 | 2023-12-20 | Janssen Pharmaceutica NV | RAPAMYCIN ANALOGS AND THEIR USES |
| CN115776907B (zh) | 2020-03-27 | 2025-02-25 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| CN121426814A (zh) * | 2020-07-21 | 2026-01-30 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| WO2024211738A1 (en) * | 2023-04-07 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Selective rapamycin analogs and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| BR9408323A (pt) | 1993-12-17 | 1997-08-19 | Sandoz Ag | Derivados de rapamicina |
| US6187757B1 (en) * | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| WO1999036553A2 (en) * | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
| IL147803A0 (en) * | 1999-08-24 | 2002-08-14 | Ariad Gene Therapeutics Inc | 28-epirapalogs |
| EP1896075A2 (en) | 2005-06-22 | 2008-03-12 | LifeCycle Pharma A/S | Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor |
| GB0601406D0 (en) * | 2006-01-24 | 2006-03-08 | Novartis Ag | Organic Compounds |
| WO2009131631A1 (en) | 2008-04-14 | 2009-10-29 | Poniard Pharmaceuticals, Inc. | Rapamycin analogs as anti-cancer agents |
| CN103391780B (zh) * | 2011-02-16 | 2015-08-19 | 诺瓦提斯公司 | 用于治疗神经变性疾病的治疗剂的组合物 |
| WO2014153118A1 (en) * | 2013-03-14 | 2014-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1) |
| WO2015142661A1 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Regulatable chimeric antigen receptor |
| EP3193902A4 (en) | 2014-09-11 | 2018-03-28 | The Regents of The University of California | mTORC1 INHIBITORS |
| US20190022073A1 (en) | 2015-09-03 | 2019-01-24 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition comprising rapamycin or derivative thereof |
| US10683308B2 (en) * | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| CN108926533B (zh) | 2017-05-24 | 2022-03-25 | 江苏天士力帝益药业有限公司 | 一种替西罗莫司脂质体及其制备方法 |
| US10478561B2 (en) | 2017-08-03 | 2019-11-19 | Minhong Yu | Wireless transmission system with integrated sensing capability |
| UY37900A (es) * | 2017-09-26 | 2019-04-30 | Novartis Ag | Nuevos derivados de rapamicina |
| US10980784B2 (en) * | 2018-06-15 | 2021-04-20 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| WO2020076738A2 (en) | 2018-10-12 | 2020-04-16 | Bellicum Pharmaceuticals, Inc | Protein-binding compounds |
| LT3898637T (lt) | 2018-12-18 | 2025-03-10 | Novartis Ag | Rapamicino dariniai |
| CA3127448C (en) | 2019-01-22 | 2024-06-04 | Aeovian Pharmaceuticals, Inc. | Mtorc modulators and uses thereof |
| EP4069223A4 (en) | 2019-12-05 | 2023-12-20 | Janssen Pharmaceutica NV | RAPAMYCIN ANALOGS AND THEIR USES |
| CN115776907B (zh) | 2020-03-27 | 2025-02-25 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| CN121426814A (zh) | 2020-07-21 | 2026-01-30 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| JP2024503898A (ja) | 2021-01-22 | 2024-01-29 | ヤンセン ファーマシューティカ エヌ．ベー． | ラパマイシン類似体及びその使用 |
-
2021
- 2021-03-26 CN CN202180038254.0A patent/CN115776907B/zh active Active
- 2021-03-26 CA CA3173722A patent/CA3173722A1/en active Pending
- 2021-03-26 IL IL296828A patent/IL296828A/en unknown
- 2021-03-26 KR KR1020227036354A patent/KR102805250B1/ko active Active
- 2021-03-26 CN CN202510123209.5A patent/CN119954829A/zh active Pending
- 2021-03-26 WO PCT/US2021/024536 patent/WO2021195599A1/en not_active Ceased
- 2021-03-26 JP JP2023502874A patent/JP7606591B2/ja active Active
- 2021-03-26 AU AU2021241718A patent/AU2021241718B2/en active Active
- 2021-03-26 EP EP21775952.1A patent/EP4126229A4/en active Pending
- 2021-03-26 MX MX2022011964A patent/MX2022011964A/es unknown
- 2021-03-26 KR KR1020257014654A patent/KR102963519B1/ko active Active
-
2022
- 2022-03-01 US US17/683,549 patent/US11634432B2/en active Active
- 2022-06-03 US US17/832,240 patent/US11603377B2/en active Active
- 2022-10-03 ZA ZA2022/10888A patent/ZA202210888B/en unknown
-
2023
- 2023-03-08 US US18/180,517 patent/US20240002399A1/en active Pending
-
2024
- 2024-12-13 JP JP2024218609A patent/JP7645431B2/ja active Active
-
2025
- 2025-06-25 AU AU2025204768A patent/AU2025204768C1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021241718B2 (en) | 2025-03-27 |
| US11603377B2 (en) | 2023-03-14 |
| KR20250065937A (ko) | 2025-05-13 |
| WO2021195599A1 (en) | 2021-09-30 |
| JP7645431B2 (ja) | 2025-03-13 |
| CN119954829A (zh) | 2025-05-09 |
| KR20230084095A (ko) | 2023-06-12 |
| KR102805250B1 (ko) | 2025-05-08 |
| AU2025204768B2 (en) | 2025-08-07 |
| EP4126229A4 (en) | 2024-04-17 |
| KR102963519B1 (ko) | 2026-05-11 |
| AU2025204768C1 (en) | 2026-02-05 |
| IL296828A (en) | 2022-11-01 |
| US20220332727A1 (en) | 2022-10-20 |
| US11634432B2 (en) | 2023-04-25 |
| AU2025204768A1 (en) | 2025-07-17 |
| JP2025028197A (ja) | 2025-02-28 |
| BR112022019508A2 (pt) | 2022-11-16 |
| JP7606591B2 (ja) | 2024-12-25 |
| JP2023530778A (ja) | 2023-07-19 |
| US20220235069A1 (en) | 2022-07-28 |
| AU2021241718A1 (en) | 2022-10-20 |
| US20240002399A1 (en) | 2024-01-04 |
| ZA202210888B (en) | 2024-02-28 |
| CA3173722A1 (en) | 2021-09-30 |
| CN115776907A (zh) | 2023-03-10 |
| EP4126229A1 (en) | 2023-02-08 |
| CN115776907B (zh) | 2025-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2026004964A2 (es) | Moduladores de kras | |
| CL2021001575A1 (es) | Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1) | |
| ECSP19021312A (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos | |
| CL2024001022A1 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| CO2023010023A2 (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| CL2018000687A1 (es) | Nuevos compuestos bicíclicos como inhibidores de atx. | |
| CL2020002573A1 (es) | Inhibidores atf6 y sus usos. | |
| CO2026004213A2 (es) | Compuestos de piridona y método de preparación de los mismos y aplicación | |
| MX2019013308A (es) | Composiciones y compuestos terapeuticos, y metodos para su uso. | |
| ZA202210888B (en) | Mtorc1 modulators and uses thereof | |
| CL2022001111A1 (es) | Degradadores de moléculas pequeñas de helios y procedimientos de uso | |
| CU20150118A7 (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
| UY36153A (es) | ?inhibidores de la fosfoinosítido 3-quinasa delta para su uso en el tratamiento de una enfermedad cutánea inmunoampollosa mediada por autoanticuerpos? | |
| CL2018003260A1 (es) | Compuestos de bencenosulfonamida y sus usos como agentes terapéuticos. | |
| CL2019001481A1 (es) | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos. | |
| BR112022010754A2 (pt) | Análogos de rapamicina e usos dos mesmos | |
| MX2022001697A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
| CL2023000371A1 (es) | Composiciones y métodos para inhibir la expresión de plp1. | |
| CL2022002402A1 (es) | Inhibidores del eif4e y sus usos | |
| MX2022004143A (es) | Compuesto que tiene actividad inhibidora de brd4, su método de preparación y su uso. | |
| CO2021007173A2 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| CO2021002225A2 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| CO6630193A2 (es) | Inhibidores de la actividad de la proteína tirosina quinasa seleccionada | |
| MX2020011405A (es) | Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos. |